UY27852A1 - Difenilazatidinonas cationicamente sustituidas, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso. - Google Patents

Difenilazatidinonas cationicamente sustituidas, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.

Info

Publication number
UY27852A1
UY27852A1 UY27852A UY27852A UY27852A1 UY 27852 A1 UY27852 A1 UY 27852A1 UY 27852 A UY27852 A UY 27852A UY 27852 A UY27852 A UY 27852A UY 27852 A1 UY27852 A1 UY 27852A1
Authority
UY
Uruguay
Prior art keywords
compounds
difenilazatidinonas
cationicamente
medicines
understand
Prior art date
Application number
UY27852A
Other languages
English (en)
Inventor
Dr Gerhard Jaehne
Dr Wendelin Frick
Dr Stefanie Flohr
Dr Andreas Lindenschmidt
Dr Heiner Glombik
Prof Dr Werner Kramer
Dr Hubert Heuer
Dr Hans-Ludwig Schaefer
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of UY27852A1 publication Critical patent/UY27852A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

Difenilazetidinonas catiónicamente sustituidas, procedimiento para su preparación, medicamentos que comprenden estos compuestos y su uso La invención se refiere a compuestos de la fórmula I, en que R1, R2, R3, R4, R5 y R6 tienen los significados dados anteriormente, y a sus sales fisiológicamente aceptables. Los compuestos son adecuados para uso, por ejemplo, como hipolipidémicos.
UY27852A 2002-06-19 2003-06-16 Difenilazatidinonas cationicamente sustituidas, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso. UY27852A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10227507A DE10227507A1 (de) 2002-06-19 2002-06-19 Kationisch substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung

Publications (1)

Publication Number Publication Date
UY27852A1 true UY27852A1 (es) 2003-12-31

Family

ID=29719282

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27852A UY27852A1 (es) 2002-06-19 2003-06-16 Difenilazatidinonas cationicamente sustituidas, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.

Country Status (26)

Country Link
EP (1) EP1517890B1 (es)
JP (1) JP2005533071A (es)
KR (1) KR20050010061A (es)
CN (1) CN1662494A (es)
AT (1) ATE401304T1 (es)
AU (1) AU2003238209B2 (es)
BR (1) BR0311984A (es)
CA (1) CA2490108A1 (es)
DE (2) DE10227507A1 (es)
DK (1) DK1517890T3 (es)
ES (1) ES2310662T3 (es)
HR (1) HRP20041202A2 (es)
IL (1) IL165790A (es)
MA (1) MA27251A1 (es)
MX (1) MXPA04012308A (es)
NO (1) NO20050088L (es)
PA (1) PA8575601A1 (es)
PL (1) PL372660A1 (es)
PT (1) PT1517890E (es)
RS (1) RS108604A (es)
RU (1) RU2315753C2 (es)
SV (1) SV2004001555A (es)
TW (1) TW200406380A (es)
UY (1) UY27852A1 (es)
WO (1) WO2004000803A1 (es)
ZA (1) ZA200409379B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
SA04250427A (ar) 2003-12-23 2005-12-03 استرازينيكا ايه بي مشتقات ثاني فينيل أزيتيدون
CN102633730A (zh) 2004-12-03 2012-08-15 先灵公司 作为cb1拮抗剂的取代哌嗪
WO2006107936A1 (en) * 2005-04-04 2006-10-12 Pontificia Universidad Catolica De Chile The use of ezetimibe in the prevention and treatment of cholesterol gallstones
KR20080021082A (ko) 2005-06-20 2008-03-06 쉐링 코포레이션 히스타민 ｈ3 길항제로서 유용한 피페리딘 유도체
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
AR060623A1 (es) 2006-04-27 2008-07-02 Astrazeneca Ab Compuestos derivados de 2-azetidinona y un metodo de preparacion
CA2666193A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use
DE102007002260A1 (de) 2007-01-16 2008-07-31 Sanofi-Aventis Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
EP2310372B1 (en) 2008-07-09 2012-05-23 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
CA2754384A1 (en) 2009-03-06 2010-09-10 Lipideon Biotechnology Ag Pharmaceutical hypocholesterolemic compositions
CN101993403B (zh) 2009-08-11 2012-07-11 浙江海正药业股份有限公司 氮杂环丁酮类化合物及医药应用
EP2470552B1 (en) 2009-08-26 2013-11-13 Sanofi Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10042447A1 (de) * 2000-08-29 2002-03-28 Aventis Pharma Gmbh Protein aus dem Darm von Wirbeltieren, welches Cholesterin absorbiert, sowie Verwendung dieses Proteins zur Identifizierung von Inhibitoren des intestinalen Cholesterintransports
CZ20031733A3 (cs) * 2000-12-21 2003-09-17 Aventis Pharma Deutschland Gmbh Difenylazetidinonové deriváty a farmaceutické prostředky s jejich obsahem
IL156550A0 (en) * 2000-12-21 2004-01-04 Aventis Pharma Gmbh Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
IL156552A0 (en) * 2000-12-21 2004-01-04 Aventis Pharma Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use

Also Published As

Publication number Publication date
MXPA04012308A (es) 2005-02-25
RS108604A (en) 2007-02-05
DK1517890T3 (da) 2008-11-10
IL165790A (en) 2010-04-15
RU2315753C2 (ru) 2008-01-27
JP2005533071A (ja) 2005-11-04
NO20050088L (no) 2005-01-06
CN1662494A (zh) 2005-08-31
CA2490108A1 (en) 2003-12-31
EP1517890A1 (de) 2005-03-30
PL372660A1 (en) 2005-07-25
ES2310662T3 (es) 2009-01-16
WO2004000803A1 (de) 2003-12-31
DE10227507A1 (de) 2004-01-08
PA8575601A1 (es) 2004-02-07
RU2005101088A (ru) 2005-06-27
ATE401304T1 (de) 2008-08-15
EP1517890B1 (de) 2008-07-16
AU2003238209B2 (en) 2009-01-22
KR20050010061A (ko) 2005-01-26
SV2004001555A (es) 2004-03-19
AU2003238209A1 (en) 2004-01-06
HRP20041202A2 (en) 2005-06-30
ZA200409379B (en) 2006-05-31
BR0311984A (pt) 2005-04-26
PT1517890E (pt) 2008-10-14
MA27251A1 (fr) 2005-03-01
IL165790A0 (en) 2006-01-15
TW200406380A (en) 2004-05-01
DE50310161D1 (de) 2008-08-28

Similar Documents

Publication Publication Date Title
UY27852A1 (es) Difenilazatidinonas cationicamente sustituidas, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.
UY28342A1 (es) Nuevos compuestos
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
AR028948A1 (es) Compuestos novedosos
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
ECSP055671A (es) Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesteresa
UY29886A1 (es) Derivados de pirazol novedosos, composiciones farmaccuticas que los contienen, procedimientos para la preparacinn de los mismos y aplicaciones
BRPI0408347B8 (pt) derivados de pirimidina, seu uso, e composição e combinação farmacêuticas
ECSP077271A (es) Derivados de pirimidina
ATE433447T1 (de) Pyrimiidinverbindungen
UY27516A1 (es) Bencimidazoles
SE0301653D0 (sv) Novel compounds
CR11857A (es) Compuestos pirazolicos 436
UY29234A1 (es) Derivados de adamantano, composiciones farmacéuticas que los contienen, procedimientos de preparación de ambos y aplicaciones.
ECSP077259A (es) Derivados de pirimidina
EA200501268A1 (ru) Ингибирующие вич 1,2,4-триазины
EA200801011A1 (ru) Производные пиразина как модуляторы натриевых каналов для лечения боли
UY29370A1 (es) Derivados de tiazol, composiciones que lo contienen, procedimientos de preparación y aplicaciones
UY27851A1 (es) Difenilazetidinonas sustituidas en anillo, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.
SE0302139D0 (sv) Novel compounds
UY28694A1 (es) Nuevos compuestos
TNSN06012A1 (en) Emulsifying systems containing azetidine derivatives
PA8568101A1 (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso
SE0302546D0 (sv) New compounds
CR9391A (es) Derivados de indanil-piperazinas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen